Tempest Therapeutics Inc. is a clinical-stage oncology company that develops small molecule therapeutics for cancer treatment. Two of its clinical programs, TPST-1495 and TPST-1120, are in Phase 1 trials for solid tumors. The company also works on developing TREX-1, a cellular enzyme that regulates the innate immune response in tumors.